Ratings by Piper Sandler (Allison Bratzel)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 9/8/2026 | Tyra Biosciences | TYRA | Maintain | Overweight (N/A) |
|
Details | ||
| 8/17/2026 | Rigel Pharmaceuticals | RIGL | Maintain | Neutral (N/A) |
|
Details | ||
| 7/31/2026 | Replimune Group | REPL | Upgrade | Overweight (Neutral) |
5.41 (12.92) |
138.82% | Details | |
| 5/8/2026 | Engene Holdings Inc. | ENGN | Downgrade | Neutral (Overweight) |
8.85 (1.80) |
-79.66% | Details | |
| 5/1/2026 | Engene Holdings Inc. | ENGN | Maintain | Overweight (N/A) |
|
Details | ||
| 4/16/2026 | Roivant Sciences | ROIV | Maintain | Overweight (N/A) |
|
Details | ||
| 4/10/2026 | Replimune Group | REPL | Downgrade | Neutral (Overweight) |
5.91 (5.41) |
-8.46% | Details | |
| 3/26/2026 | Tyra Biosciences | TYRA | Maintain | Overweight (N/A) |
|
Details | ||
| 3/20/2026 | Tyra Biosciences | TYRA | Maintain | Overweight (N/A) |
|
Details | ||
| 3/4/2026 | Scholar Rock | SRRK | Maintain | Overweight (N/A) |
|
Details | ||
| 2/5/2026 | Replimune Group | REPL | Maintain | Overweight (N/A) |
|
Details | ||
| 1/23/2026 | Tyra Biosciences | TYRA | Maintain | Overweight (N/A) |
|
Details | ||
| 10/20/2025 | Replimune Group | REPL | Upgrade | Overweight (Neutral) |
4.50 (5.91) |
31.33% | Details | |
| 9/24/2025 | Scholar Rock | SRRK | Maintain | Overweight (N/A) |
|
Details | ||
| 8/22/2025 | Ionis Pharmaceuticals | IONS | Maintain | Overweight (N/A) |
|
Details | ||
| 7/22/2025 | Replimune Group | REPL | Downgrade | Neutral (Overweight) |
12.32 (12.92) |
4.87% | Details | |
| 6/2/2025 | Replimune Group | REPL | Maintain | Overweight (N/A) |
|
Details | ||
| 5/21/2025 | Tyra Biosciences | TYRA | New Coverage | Overweight (N/A) |
9.98 (22.03) |
120.74% | Details | |
| 4/23/2025 | Scholar Rock | SRRK | Maintain | Overweight (N/A) |
|
Details | ||
| 2/17/2025 | Engene Holdings Inc. | ENGN | New Coverage | Overweight (N/A) |
6.25 (8.85) |
41.6% | Details | |
| 12/23/2024 | Ionis Pharmaceuticals | IONS | Maintain | Overweight (N/A) |
|
Details | ||
| 10/15/2024 | Scholar Rock | SRRK | Maintain | Overweight (N/A) |
|
Details | ||
| 8/19/2024 | Q32 Bio Inc. | QTTB | Maintain | Overweight (N/A) |
|
Details | ||
| 7/18/2024 | Roivant Sciences | ROIV | Maintain | Overweight (N/A) |
|
Details | ||
| 7/10/2024 | Roivant Sciences | ROIV | Maintain | Overweight (N/A) |
|
Details | ||
| 6/4/2024 | Scholar Rock | SRRK | Maintain | Overweight (N/A) |
|
Details | ||
| 5/31/2024 | Roivant Sciences | ROIV | Maintain | Overweight (N/A) |
|
Details | ||
| 5/23/2024 | Scholar Rock | SRRK | Maintain | Overweight (N/A) |
|
Details | ||
| 4/2/2024 | Q32 Bio Inc. | QTTB | New Coverage | Overweight (N/A) |
17.04 (3.15) |
-81.51% | Details | |
| 2/8/2024 | Replimune Group | REPL | Maintain | Overweight (N/A) |
|
Details | ||
| 1/18/2024 | Ionis Pharmaceuticals | IONS | Maintain | Overweight (N/A) |
|
Details | ||
| 1/5/2024 | Roivant Sciences | ROIV | New Coverage | Overweight (N/A) |
10.86 (40.82) |
275.87% | Details | |
| 11/14/2023 | Incyte | INCY | Maintain | Overweight (N/A) |
|
Details | ||
| 6/7/2023 | Ionis Pharmaceuticals | IONS | New Coverage | Overweight (N/A) |
42.26 (54.21) |
28.28% | Details | |
| 4/17/2023 | Replimune Group | REPL | New Coverage | Overweight (N/A) |
16.27 (12.92) |
-20.59% | Details | |
| 4/3/2023 | Rigel Pharmaceuticals | RIGL | New Coverage | Neutral (N/A) |
1.34 (47.24) |
3425.37% | Details | |
| 4/3/2023 | Scholar Rock | SRRK | New Coverage | Overweight (N/A) |
7.65 (55.41) |
624.31% | Details | |
| 1/31/2023 | Incyte | INCY | New Coverage | Overweight (N/A) |
85.70 (121.47) |
41.74% | Details |
